PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product
ConditionChronic Pain
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age21+
SponsorStaci Gruber, Ph.D.
About this trial
This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.
Eligibility criteria
Qualifiers
Subject has provided informed consent
Subject is 21 or older
Subject is fluent in English
Subject endorses a musculoskeletal chronic pain condition including, but not limited to, chronic pain due to injury, arthritis (including osteoarthritis and rheumatoid arthritis), bursitis, etc.
Disqualifiers
Non-fluent English speakers
Estimated IQ < 75
A history of head injury or loss of consciousness greater than 5 minutes
Currently uses CBD products regularly
Trial design
Treatments tested in this trial
- Cannabidiol
- Placebo
Treatment groups
25 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov